Email updates

Keep up to date with the latest news and content from BMC Systems Biology and BioMed Central.

Open Access Highly Accessed Research article

Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug

Hee Sook Lee16, Taejeong Bae126, Ji-Hyun Lee126, Dae Gyu Kim1, Young Sun Oh1, Yeongjun Jang3, Ji-Tea Kim3, Jong-Jun Lee1, Alessio Innocenti4, Claudiu T Supuran4, Luonan Chen5, Kyoohyoung Rho3* and Sunghoon Kim12*

Author Affiliations

1 Medicinal Bioconvergence Research Center, College of Pharmacy, Seoul National University, Seoul, Korea

2 World Class University Program Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, 151-742, Korea

3 Information Center for Bio-pharmacological Network, Seoul National University, Suwon, Korea

4 Dipartimento di Chimica Laboratorio di Chimica Bioinorganica, University of Florence, Via della Lastruccia, 3, Rm. 188 Polo Scientifico, Sesto Fiorentino (Firenze), 50019, Italy

5 Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200233, China

6 Medicinal Bioconvergence Research Center, Advanced Institutes of Convergence Technology, Suwon, 443-270, Korea

For all author emails, please log on.

BMC Systems Biology 2012, 6:80  doi:10.1186/1752-0509-6-80

Published: 2 July 2012

Abstract

Background

The process of drug discovery and development is time-consuming and costly, and the probability of success is low. Therefore, there is rising interest in repositioning existing drugs for new medical indications. When successful, this process reduces the risk of failure and costs associated with de novo drug development. However, in many cases, new indications of existing drugs have been found serendipitously. Thus there is a clear need for establishment of rational methods for drug repositioning.

Results

In this study, we have established a database we call “PharmDB” which integrates data associated with disease indications, drug development, and associated proteins, and known interactions extracted from various established databases. To explore linkages of known drugs to diseases of interest from within PharmDB, we designed the Shared Neighborhood Scoring (SNS) algorithm. And to facilitate exploration of tripartite (Drug-Protein-Disease) network, we developed a graphical data visualization software program called phExplorer, which allows us to browse PharmDB data in an interactive and dynamic manner. We validated this knowledge-based tool kit, by identifying a potential application of a hypertension drug, benzthiazide (TBZT), to induce lung cancer cell death.

Conclusions

By combining PharmDB, an integrated tripartite database, with Shared Neighborhood Scoring (SNS) algorithm, we developed a knowledge platform to rationally identify new indications for known FDA approved drugs, which can be customized to specific projects using manual curation. The data in PharmDB is open access and can be easily explored with phExplorer and accessed via BioMart web service (http://www.i-pharm.org/ webcite, http://biomart.i-pharm.org/ webcite).

Keywords:
Tripartite network; Drug repositioning; Shared Neighborhood Scoring (SNS) algorithm